SomaLogic Operating announced its partnership with Dante Genomics, a global leader in genomics and precision medicine, to offer a comprehensive solution for proteomics testing at scale in Europe. Dante will be the first SomaLogic authorized site in Italy. Dante Genomics will run SomaLogic’s technology out of its laboratory in Italy, providing proteomics services for the European market. SomaLogic’s 7,000-plex SomaScan Platform can be applied across research and discovery. It can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. SomaLogic and Dante Genomics will partner to offer one of the first multiomic capabilities to support clinical research discovery, expanding the databases and total addressable market for both companies.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLGC:
- SomaLogic to Announce Second Quarter 2023 Financial Results on August 14, 2023
- SomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in Europe
- SomaLogic Partners with Citogen to Expand Authorized Site Program in Europe
- SomaLogic, Citogen partner to expand authorized site program in Europe
- SomaLogic Announces Chief Financial Officer Transition